Member Info for Desouzaa

A lot of maybe‘s and what if‘s after „the whistleblowing“ or „Scancell Statement“.

Now one from me.

Maybe or what if the NEUP Merger is only for Glymab Therapeutics and not the whole Holding… 🤔

The last trade, 20k @16.80, is a buy and isnt uncrossed…

I couldn’t resist during the dip either. Let’s wait and see if that was a smart move in the short term. In the long term without hesitation.

I’m going to make a comparison that might sound a bit odd.

At the moment, I see Scancell, with all its ideas and its pipeline, as a sort of salt, pepper and lemon – basically a ‘flavour enhancer’ for MANY things – or like potatoes or pasta, etc., essentially a ‘side dish’ for MANY things.

To be honest, I think and dream that the whole thing also has the potential to become a Beef Wellington in its own right…

…at least parts of it. And pasta or potatoes can be the main course sometimes too🤷🏻‍♂️

To explain: I’m 185cm tall and weigh a hefty 120kg😁😉

Joking aside. How wonderful it would be if it could help lots and lots of people. I have a case in my own immediate circle and you’re grateful for any help.

Hello everyone. I’ve got a question. It’s probably been answered before, but it doesn’t hurt to ask. We’ve got plenty of expertise here on the forum.

In the January RNS, the PFS comparison still shows ISCIB1+ at 74% after 16 months versus Soc at 50% after 11.5 months.

In today’s RNS, we have the direct comparison after 20 months. That stands at 77% ISCIB1+ versus 43% Soc.

A 34% increase in PFS after 20 months… that’s massive💪🏼💪🏼

The same figures viewed from a different angle are even more IMPRESSIVE…

The 34% increase is, in a ‘direct comparison’ to the 43% for Soc, actually an almost 80% increase…WOWWWW

If, in my enthusiasm, I’ve misunderstood anything, please correct me.

So far, the findings; now my question.

Since PFS is rising in the ISCIB1+ group and falling in the Soc group over time, it is therefore possible that, in further patients in the study, ISCIB1+ will ensure that the tumour does not grow any further (based on the previous figures), thus increasing PFS, whilst in the Soc group, PFS could presumably fall (based on the previous figures), causing the gap to widen even further…

I’m honestly totally hyped right now. Please correct me if anything is wrong.

As I said, a lot is possible here.

I think there are some very clever people working at Scancell, both the scientists and the management/board of directors.

In addition, ALL data from ALL trials to date has been consistently positive. Although still small, it is consistently positive.

And there is still a lot in the pipeline, plus certainly a lot more to come in the future.

In addition, it should be noted that the patients treated and the diseases treated are severe cases. If you start earlier and also treat "simpler" diseases, much more is possible, of course.

And now remember that

much more is possible with monotherapy. That is also within the realm of possibility.

But it is also possible that everything will go down the drain and flop. That is my view of things...

So @Ruck. As I wrote at the beginning, a lot is possible here. Both a total crash and £8.

I don't know yet when I'll get out if it goes really well. But I'm somehow sure of one thing. The grin on my face will be bigger than when I got out of Cidara😁😏😎

Sorry if some of what I write is a bit incomprehensible or superficial, but my English skills are unfortunately limited, so here's my excuse: the Deepl translator...😉

THX @TakeStock

No, no. Warren didnt enter new here. Warren has been here for about 1.5 years😉 and has been investing in Scancell since the beginning of Corona, so since about 2020.

I don't have a time limit for Scancell. Nor do I have a target price at which I would sell.

The £1 target mentioned in the chat here sounds like music to my ears. However, I think Scancell has the potential to reach the £8 target that is sometimes mentioned and ridiculed here. Maybe even more...

It sounds like a pipe dream. I know. But we shouldn't let ourselves be deprived of dreams and goals/desires in a stressful environment at this stressful time...

For me personally, the difference between Scancell and Cidara is that I bought into Cidara at €10 about three years ago and said goodbye to Cidara on Friday with a big smile on my face.

Cidara is not just about the flu medicine. Rezafungin, their approved product, is also good stuff and still has huge potential...

I hold Scancell at an average price of 9 pence, but to be honest, my expectations for Scancell are higher than my expectations for Cidara...

For your information, I am also well invested in Iovance at $1.7 and expect the company to be sold at some point...

Greetings to Phil, Lindy and the others…😉

A question regarding the Scancell study. Is it not a problem that this is an open-label study? Ultimately, phase 3 will be decisive, that much is clear. It will certainly be blinded.

If I'm not mistaken, Evaxion also had the problem that they probably don't have the money to "expand" the study to more patients. I read that in one of the articles.

Evaxion's share price also took a nosedive yesterday, despite good figures. This was certainly due to the reduction in the number of patients and the fact that the primary endpoint cannot be measured/determined as a result.

Hey Moon. Isn't that the problem with all personalised vaccines?

It takes time before treatment can begin. That shouldn't be a problem for less aggressive diseases. But the more aggressive the disease, the more problematic I think it is.

Advanced Melanoma Peptid based Vaccine Evaxion

https://finance.yahoo.com/news/evaxion-reports-75-objective-response-121500543.html

Wow wow wow. That smacks of professionalism. Our CEO and his team are doing an impressive job. By far the most professional, structured and informative RNS I have received in 6 years of holding Scancell shares. The only thing missing is the sentence "any other questions?" at the end😁😉

Good Job. Keep it up. Strong💪.

Couldn't resist it either😁 Once again🤷🏻‍♂️ But my 32K are not shown at all... 🤔

Thats my favourite. Concentrated Expertise.

https://www.england.nhs.uk/2025/04/skin-cancer-patients-fast-tracked-access-revolutionary-nhs-cancer-vaccine-trial/

„Revolutionary“…

Sounds like music to my ears from the mouths of important experts and key decision-makers...

This spreads quickly

https://www.theguardian.com/society/2025/apr/14/melanoma-patients-in-england-get-fast-track-access-to-cancer-vaccine

https://www.bbc.com/news/articles/c2kvq89020jo.amp

https://www.telegraph.co.uk/news/2025/04/14/nhs-trials-skin-cancer-vaccine-melanoma-personal-treatment/

https://www.independent.co.uk/news/health/melanoma-vaccine-skin-cancer-nhs-b2732575.html

And so on…

My confidence in the company has increased again today. Just like my shares…😁😉

@violindog

This is Geovax…

The reason for their rise is because they are working on a monkeypox vaccine. Incidentally, I am also invested there and in Bavarian Nordic for the same reason.

And I'm looking at Siga Technologies and Tonix Pharma.

Https://www.removepaywall.com/search?url=https://www.dailymail.co.uk/health/article-13738469/vaccine-beat-cancer-MATT-RIDLEY-reveals-Britain-leading-gold-rush-new-therapies.html

normally that's not my style but since he/she wrote so much bull****. where the hell is @scinv?!?!😉

so now back to the topic. #let’s go lindy #let's go scancell🤭🤗